In Brief: Bio-Technology General Corp.
This article was originally published in The Gray Sheet
Executive Summary
Bio-Technology General Corp.: Firm's premarket approval application for its BioLon viscoelastic 1% solution of sodium hyaluronate for use in ophthalmic surgery procedures is accepted for filing by FDA. Data used to support the PMA was gathered overseas, the company says. Currently, the product is sold in 17 countries outside the U.S. for use in procedures including: intraocular lens insertion, intracapsular and extracapsular lens extraction, glaucoma surgery, corneal graft surgery, retinal detachment and vitreal replacement...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.